ADNI data is made available to researchers around the world. As such, there are many active research projects accessing and applying the shared ADNI data. To further encourage Alzheimer’s disease research collaboration, and to help prevent duplicate efforts, the list below shows the specific research focus of the active ADNI investigations. This information is requested annually as a requirement for data access.
| Principal Investigator | |
| Principal Investigator's Name: | Alex Agyemang |
| Institution: | Barts and the London School of Medicine and Dentistry |
| Department: | Clinical Pharmacology |
| Country: | |
| Proposed Analysis: | The objectives of my research study are to: â?¢Investigate the pharmacokinetic and pharmacodynamic (PK/PD) relationships of the acetylcholinesterase (AChE) inhibitors and other class of drugs used in the treatment of Alzheimer's disease and other dementia disorders. â?¢Perform a meta-analysis of the AChE inhibitors and construct a model that can be used as a 'reference' to predict the PK/PD profile of novel antidementia compounds in humans. To facilitate this research, I am interested in patient-level data to assess both inter-subject variability and mean response. â?¢Investigate the possible sources of pharmacokinetic or pharmacodynamic drug-drug interactions involving AChE inhibitors and other class of drugs used in the treatment of Alzheimer's disease and other dementia disorders. â?¢Investigate in silico models which may offer the possibility of simulating the pharmacodynamic effects of anti-dementia drugs in specific areas of the brain. This will be helpful in distinguishing purely symptomatic effects from disease-modifying effects, the latter being the ultimate goal of the modern pharmacology of dementia. |
| Additional Investigators |